The Swedish biotech company develops therapies targeting underlying disease mechanisms, with a focus on more precise treatments for autoimmune diseases such as rheumatoid arthritis.

“We are honored to receive this award. The collaboration with AbbVie and Karolinska Institutet Innovation provides valuable expertise and networks to help accelerate our development,” says Ulrika Norin, CEO of SerendoTx.

AbbVie’s Golden Ticket program supports early-stage companies in advancing and commercializing drug candidates within its core areas, including immunology, oncology, neuroscience, ophthalmology, and aesthetics.

Following a competitive call that attracted a large number of high-quality applications, SerendoTx was selected after evaluation and interviews.

“We were impressed by the overall quality of applications and look forward to working closely with SerendoTx, which we believe has a promising approach in autoimmune disease,” says Matthew Iles, CEO of AbbVie Scandinavia.

As part of the program, SerendoTx will receive a one-year incubation at Karolinska Institutet Innovation, including access to lab and office space in Hagastaden, as well as mentorship, business support, and access to AbbVie’s and KI Innovation’s networks.